Romano Danesi
TitleCited byYear
Molecular basis of resistance to azole antifungals
A Lupetti, R Danesi, M Campa, M Del Tacca, S Kelly
Trends in molecular medicine 8 (2), 76-81, 2002
4312002
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity
E Giovannetti, N Funel, GJ Peters, M Del Chiaro, LA Erozenci, E Vasile, ...
Cancer research 70 (11), 4528-4538, 2010
4072010
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine
E Giovannetti, M Del Tacca, V Mey, N Funel, S Nannizzi, S Ricci, ...
Cancer research 66 (7), 3928-3935, 2006
3532006
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy
A Sparreboom, R Danesi, Y Ando, J Chan, WD Figg
Drug Resistance Updates 6 (2), 71-84, 2003
2562003
Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients
C Tibaldi, E Giovannetti, E Vasile, V Mey, AC Laan, S Nannizzi, ...
Clinical Cancer Research 14 (6), 1797-1803, 2008
2472008
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non–small-cell lung cancer cells
E Giovannetti, V Mey, S Nannizzi, G Pasqualetti, L Marini, M Del Tacca, ...
Molecular pharmacology 68 (1), 110-118, 2005
2282005
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs
R Danesi, S Fogli, A Gennari, P Conte, M Del Tacca
Clinical pharmacokinetics 41 (6), 431-444, 2002
2112002
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer
A Hamada, T Sissung, DK Price, R Danesi, CH Chau, N Sharifi, D Venzon, ...
Clinical Cancer Research 14 (11), 3312-3318, 2008
1702008
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors
L Jain, CA Vargo, R Danesi, TM Sissung, DK Price, D Venzon, J Venitz, ...
Molecular cancer therapeutics 8 (9), 2496-2508, 2009
1692009
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate …
E Giovannetti, C Lemos, C Tekle, K Smid, S Nannizzi, JA Rodriguez, ...
Molecular pharmacology 73 (4), 1290-1300, 2008
1692008
Cardiac toxicity of antineoplastic anthracyclines
R Zucchi, R Danesi
Current Medicinal Chemistry-Anti-Cancer Agents 3 (2), 151-171, 2003
1642003
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer
A Falcone, G Masi, G Allegrini, R Danesi, E Pfanner, IM Brunetti, ...
Journal of clinical oncology 20 (19), 4006-4014, 2002
1642002
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
F Crea, EM Hurt, LA Mathews, SM Cabarcas, L Sun, VE Marquez, ...
Molecular cancer 10 (1), 40, 2011
1522011
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis
F Crea, L Fornaro, G Bocci, L Sun, WL Farrar, A Falcone, R Danesi
Cancer and Metastasis Reviews 31 (3-4), 753-761, 2012
1362012
Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995).
R Danesi, C Agen, U Benelli, AD Paolo, D Nardini, G Bocci, F Basolo, ...
Clinical Cancer Research 3 (2), 265-272, 1997
1341997
Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38
L Paoluzzi, AS Singh, DK Price, R Danesi, RHJ Mathijssen, J Verweij, ...
The Journal of Clinical Pharmacology 44 (8), 854-860, 2004
1262004
Relationship between 5-fluorouracil disposition, toxicity and dihydropy rimidine dehydrogenase activity in cancer patients
AD Paolo, R Danesi, A Falcone, L Cionini, F Vannozzi, G Masi, G Allegrini, ...
Annals of oncology 12 (9), 1301-1306, 2001
1212001
CYP2D6 polymorphisms and the impact on tamoxifen therapy
JN Beverage, TM Sissung, AM Sion, R Danesi, WD Figg
Journal of pharmaceutical sciences 96 (9), 2224-2231, 2007
1192007
The pharmacological bases of the antiangiogenic activity of paclitaxel
G Bocci, A Di Paolo, R Danesi
Angiogenesis 16 (3), 481-492, 2013
1172013
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice
E Giovannetti, A Erozenci, J Smit, R Danesi, GJ Peters
Critical reviews in oncology/hematology 81 (2), 103-122, 2012
1122012
The system can't perform the operation now. Try again later.
Articles 1–20